BiOptic Inc.

NEWS

2022-03-21

Congratulations! BiOptic has received the CE-IVD approval for SARS-CoV-2 Detection System

BiOptic has received the CE-IVD approval for the Qexp-MDx Direct SARS-CoV-2 Detection Kit utilizing the Qamp-mini Thermal Cycler and Qsep Series Bio-Fragment Analyzers.

2022-01-19

BiOptic delivers 2021 results ahead of expectations, setting a new record of annual revenue

he new member of Taiwan's Emerging Stock Boards - BiOptic Inc. (6850) has announced the consolidated revenue of 26.9 million NTD in December 2021, which
rewrote a new record high. The 2021 annual consolidated revenue reached 179.28 million, with an annual increase of 45%, which went better than expected.

2021-11-30

Congratulations! BiOptic has won the 20th Pharmaceutical Technology Research & Development Award- Golden Award

The “20th Pharmaceutical Technology Research and Development (PTRD) Award” is the only award which authorized by dual central agency including the Ministry of Health and Welfare and the Ministry of Economic Affairs in Taiwan.

Video

Qsep Series Bio-Fragment Analyzer-Product Film

Qsep Series Bio-Fragment Analyzer is an affordable CGE system for all users from the fields from biotechnology research, molecular diagnostic and clinical diagnostic. It can become a personal gel electrophoresis tool and get more accurate result at sizing and concentration.

Qsep₁

Portable

Qsep₁₀₀

Single-Channel

Qsep₄₀₀

Multi-Channel

Qsep₁₀₀ Advance

Single-Channel

(P1 Cartridge Compatible)

Qamp_mini

Portable PCR Thermocycler

Cartridges

DirectGO!

Ready-To-Use for Direct PCR
2X PCR Master Mix

ExpressGO!

Ready-To-Use
2X PCR Master Mix

AccuGO!

Proofreading
DNA polymerase

More Products

APPLICATION

BiOptic is a leader in the development, manufacture and marketing of rapid, accurate and cost-effective CGE-based products for post-PCR and genotyping applications for research and clinical diagnostics use.

DNA

RNA

Protein

Glycan

Immuno Assay

Find Us

We use our own and third—party cookies to improve our experience and our services, by analysing how people use our website. By continuing to use the website, we understand that you accept their use.